Details for New Drug Application (NDA): 020337
✉ Email this page to a colleague
NDA 020337 describes TEMOVATE, which is a drug marketed by Fougera Pharms and is included in five NDAs. Additional details are available on the TEMOVATE profile page.
The generic ingredient in TEMOVATE is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
The generic ingredient in TEMOVATE is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
Summary for 020337
| Tradename: | TEMOVATE |
| Applicant: | Fougera Pharms |
| Ingredient: | clobetasol propionate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020337
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GEL;TOPICAL | Strength | 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Apr 29, 1994 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
